Business Context and Reporting Period
This Form 8-K is a current report filed by Cyclacel Pharmaceuticals, Inc. on January 11, 2013. The filing discloses a corporate action regarding the declaration of a quarterly cash dividend on the Company's 6% Convertible Exchangeable Preferred Stock.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figure disclosed is the dividend amount.
- Dividend Declared: $0.15 per share on 6% Convertible Exchangeable Preferred Stock.
- Record Date: January 22, 2013.
- Payment Date: February 1, 2013.
Material Changes
The filing reports the declaration of a dividend as a discrete event. It does not contain comparative financial data or discuss material changes in operating results versus prior periods.
Guidance, Outlook, and Risks
Management noted that the Board considered financial analysis and surplus determinations before declaring the dividend. The filing explicitly states there is no assurance that future quarterly dividends will be declared, as the Board will analyze the advisability of such declarations in future quarters.
Investor Verification Checklist
- Verify the number of outstanding shares of 6% Convertible Exchangeable Preferred Stock to calculate total dividend liability.
- Confirm the Company's current cash position to ensure ability to pay the dividend on February 1, 2013.
- Review the Company's most recent 10-K or 10-Q for detailed financial health and surplus status.
- Monitor future filings for confirmation of subsequent dividend declarations.